Výsledky vyhledávání

POS0816 DRUG SURVIVAL OF INFLIXIMAB IN BEHÇET’S SYNDROME PATIENTS WITH DIFFERENT TYPES OF INVOLVEMENT

Autor: S. N. Esatoglu, B. Tukek, S. S. Taflan, Y. Ozyazgan, D. Ucar, V. Hamuryudan, Y. Ozguler, E. Seyahi, M. Melikoglu, U. Uygunoglu, A. Siva, Z. Kutlubay, I. Fresko, S. Yurdakul, H. Yazici, G. Hatemi

Publikováno v: Annals of the Rheumatic Diseases. 81:697.2-698

BackgroundInfliximab (IFX) is an effective therapeutic option in the management of severe and refractory manifestations of Behçet’s syndrome (BS).ObjectivesWe aimed to evaluate long term drug survival of IFX in a large cohort of BS patients.Method

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ea4007c3961b6cf075baf3e612954184
https://doi.org/10.1136/annrheumdis-2022-eular.3951

Zobrazit plný text záznamu

POS0814 OUTCOME OF VASCULAR INVOLVEMENT OF BEHÇET’S SYNDROME TREATED WITH INFLIXIMAB: A RETROSPECTIVE COHORT STUDY

Autor: G. Hatemi, B. Tukek, S. N. Esatoglu, Y. Ozguler, S. S. Taflan, M. Melikoglu, S. Ugurlu, I. Fresko, Z. Kutlubay, S. Yurdakul, H. Yazici, V. Hamuryudan

Publikováno v: Annals of the Rheumatic Diseases. 81:696.2-697

BackgroundVascular involvement is the most common cause of mortality and an important cause of disability in patients with Behçet’s syndrome (BS). Cyclophosphamide has been the treatment choice for severe vascular involvement, but high frequency o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::44f385ea29f9db4880eeb7d2fa9f6299
https://doi.org/10.1136/annrheumdis-2022-eular.3836

Zobrazit plný text záznamu

POS0814 DRUG RETENTION RATE, REASONS FOR DISCONTINUATION AND OUTCOME OF INFLIXIMAB USE IN BEHÇET SYNDROME

Autor: S. S. Taflan, Yesim Ozguler, Izzet Fresko, Zekayi Kutlubay, Gulen Hatemi, B. Tukek, Didar Ucar, Sinem Nihal Esatoglu, Ugur Uygunoglu, Melike Melikoglu, Halil Yazici, Vedat Hamuryudan, Aksel Siva, Emire Seyahi, Yilmaz Ozyazgan, Sebahattin Yurdakul

Publikováno v: Annals of the Rheumatic Diseases. 80:660-661

Background:Infliximab (IFX) plays a key role in the management of severe and refractory manifestations of Behçet syndrome (BS). However we had previously shown that its sustained use may be limited due to adverse events and lack of patient complianc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1ac686abba8e3df9d43d3e3aee8f08fb
https://doi.org/10.1136/annrheumdis-2021-eular.3262

Zobrazit plný text záznamu

POS0820 INFLIXIMAB FOR VASCULAR INVOLVEMENT IN BEHÇET SYNDROME

Autor: Izzet Fresko, Melike Melikoglu, Sinem Nihal Esatoglu, B. Tukek, Serdal Ugurlu, Yesim Ozguler, S. Yurdakul, Gulen Hatemi, E. B. Caliskan, Halil Yazici, Vedat Hamuryudan

Publikováno v: Annals of the Rheumatic Diseases. 80:663-663

Background:Vascular involvement is an important cause of morbidity and mortality in patients with Behçet syndrome (BS). TNF inhibitors have been reported to be effective for almost all serious manifestations of BS but data on vascular involvement is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::52fcdd1711daa2e8e4c042f12ef9daa8
https://doi.org/10.1136/annrheumdis-2021-eular.3971

Zobrazit plný text záznamu

POS0819 EMERGENCE OF DE NOVO MANIFESTATIONS DURING INFLIXIMAB TREATMENT IN BEHÇET SYNDROME

Autor: Izzet Fresko, E. B. Caliskan, Yesim Ozguler, B. Tukek, Zekayi Kutlubay, Ugur Uygunoglu, Aksel Siva, Yilmaz Ozyazgan, Emire Seyahi, Sinem Nihal Esatoglu, Didar Ucar, Halil Yazici, Gulen Hatemi, S. Yurdakul, Melike Melikoglu, Vedat Hamuryudan

Publikováno v: Annals of the Rheumatic Diseases. 80:662.2-663

Background:Infliximab (IFX) is increasingly used in the management of severe, relapsing or refractory manifestations of Behçet Syndrome (BS). Emergence of de novo manifestations have been reported during IFX treatment, despite efficacy for the initi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5a4c69f17792f06d2826ebbe0d17d9ab
https://doi.org/10.1136/annrheumdis-2021-eular.3887

Zobrazit plný text záznamu

SAT0258 DRUG RETENTION RATE AND PROGNOSIS AFTER DISCONTINUATION OF INFLIXIMAB IN PATIENTS WITH BEHÇET SYNDROME

Autor: Halil Yazici, Sinem Nihal Esatoglu, S. S. Taflan, Melike Melikoglu, S. Yurdakul, Izzet Fresko, B. Tukek, Emire Seyahi, Vedat Hamuryudan, Yilmaz Ozyazgan, Didar Ucar, Gulen Hatemi, Aksel Siva, Ugur Uygunoglu

Publikováno v: Annals of the Rheumatic Diseases. 79:1071.2-1072

Background:Infliximab (IFX) has become an important treatment option for all manifestations of Behçet syndrome (BS). Adverse events, loss of efficacy, lack of patient compliance and cost may limit its sustained use in patients with BS.Objectives:We

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e561da7e71727890844782e52af67d09
https://doi.org/10.1136/annrheumdis-2020-eular.3299

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání